In the poorly immunogenic aggressive B16.F10 melanoma model, the TLR2 agonist, Pam3CSK4, was shown to inhibit tumor growth in a mast cell TLR2-dependent manner; tumor control was significantly reduced in the mast-cell-deficient KitW-sh/W-sh murine background or in mice with TLR2-deficient bone-marrow-derived mast cells compared to wildtype mast-cell-containing mice [92]. Here, TLR2 is linked to melanoma.